AIM: A regulatory network in the @entity1 brain mediating @entity1091 response in @entity162 @entity1 was revealed by analysis of functional SNPs from genome-wide association studies (GWAS) and published gene association studies, followed by epigenome mapping. METHODS: An initial set of 23,312 SNPs in linkage disequilibrium with lead SNPs, and sub-threshold GWAS SNPs rescued by pathway analysis, were studied in the same populations. These were assessed using our workflow and annotation by the epigenome roadmap consortium. RESULTS: Twenty-seven percent of 802 SNPs that were associated with @entity1091 response (13 published studies gene association studies and two GWAS) were shared in common with 1281 SNPs from 18 GWAS examining @entity146 and adverse events associated with @entity1091 treatment.  Nineteen SNPs were annotated as active regulatory elements such as enhancers and promoters in a tissue-specific manner. They were located within noncoding regions of ten genes: @entity16854 , @entity8713 , @entity18128 , @entity68861 , @entity994 , @entity10366 , @entity7336 , @entity9459 , @entity32226 and @entity9320 . Following gene set enrichment and pathway analysis, these genes were found to be significantly associated (p = 10(-27); Fisher exact test) with an AMPA2 @entity3264 receptor network in @entity1 brain. Our workflow results showed concordance with annotation of regulatory elements from the epigenome roadmap. Analysis of cognate mRNA and enhancer RNA exhibited patterns consistent with an integrated pathway in humanbrain. CONCLUSION: This pharmacoepigenomic regulatory pathway is located in the same brain regions that exhibit tissue volume loss in @entity162 . Although in silico analysis requires biological validation, the approach provides value for identification of candidate  variants that may be used in pharmacogenomic testing to identify @entity162 @entity1 likely to respond to @entity1091 .

A glutamatergic network mediates @entity1091 response in XXXX as defined by epigenome pathway analysis.

@entity1 :: ('9606', 'Species') :: ['human', 'patients'] @entity16854 :: ('288', 'Gene') :: ['ANK3'] @entity162 :: ('MESH:D001714', 'Disease') :: ['bipolar disorder', 'bipolar'] @entity3264 :: ('D018698', 'Chemical') :: ['glutamate'] @entity32226 :: ('9572', 'Gene') :: ['NR1D1'] @entity146 :: ('MESH:D001523', 'Disease') :: ['psychiatric disorders'] @entity8713 :: ('406', 'Gene') :: ['ARNTL'] @entity9320 :: ('6506', 'Gene') :: ['SLC1A2'] @entity7336 :: ('2891', 'Gene') :: ['GRIA2'] @entity10366 :: ('1385', 'Gene') :: ['CREB1'] @entity1091 :: ('MESH:D008094', 'Chemical') :: ['lithium'] @entity18128 :: ('775', 'Gene') :: ['CACNA1C'] @entity9459 :: ('2932', 'Gene') :: ['GSK3B'] @entity68861 :: ('10369', 'Gene') :: ['CACNG2'] @entity994 :: ('1026', 'Gene') :: ['CDKN1A']
@entity162 :: (MESH:D001714,Disease) :: ['bipolar disorder']
